Special Issue on Immunotherapy

Submission Deadline: Jan. 30, 2015

Please click the link to know more about Manuscript Preparation: http://www.ijimmunology.org/submission

  • Lead Guest Editor
    • Department of Microbiology and Immunology, All Saint University, St Vincent, Saint Vincent and the Grenadines
  • Guest Editor
    Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to complete the Guest Editor application.
  • Introduction

    The aim of this special issue titled " Immunotherapy" is to enhance effective health care delivery by giving researchers opportunity to share their recent findings in the stimulation of immune system .

    Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapy

    The active agents of immunotherapy are collectively called immunomodulators. They are diverse array of recombinants, synthetic and natural preparations, often cytokines. Some of these substances, such as granulocyte colony-stimulating factor, interferon, imiquimod and cellular membrane fractions from bacteria are already licensed for use in patens. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine oligodeoxynucleotides and glucans are currently been investigated in clinical and preclinical studies.

    Immunomodulatory regimes offer an attractive approach as they often have fewer side effects than the existing drugs, including less potential for creating resistance in microbial disease. Immune effector cells such as lymphocytes, macrophages dendritic cells, natural killer cells, cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of the tumor due to mutation.

    For this special issue; researchers are encouraged to send in their manuscripts covering the following topics:

    1. Autologous immune enhancement therapies
    2. Vaccination
    3. Cancer immunotherapy
    4. Immunosuppressive drugs
    5. Allergen immunotherapy
    6. Helminthic therapies
    7. Genetically engineered T cells
    8. T cell adoptive transfer
    9. Dendritic cell-based immunotherapy

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.ijimmunology.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.

  • Published Papers

    The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.